Skip to main content
SpringerLink
Log in

The effect of latanoprost 0.005% once daily versus 0.0015% twice daily on intraocular pressure and aqueous humour protein concentration in glaucoma patients. A randomized, double-masked comparison with timolol 0.5%

  • Clinical Investigation
  • Published:
Graefe's Archive for Clinical and Experimental Ophthalmology Aims and scope Submit manuscript

Abstract

• Background: Latanoprost is a PGF2α analogue which reduces the intraocular pressure (IOP) by increasing the uveoscleral outflow. The objective of this study was to investigate the effect of two different regimens of latanoprost on the diurnal IOP and also the effect of latanoprost on the blood-aqueous barrier measured with a laser flare cell meter (Kowa FM-500). Moreover, the safety aspects of the two regimens regarding hyperemia were studied. • Methods: A double-masked, randomized study was performed in 30 patients (9 males, 21 females; mean age 61.9 years) with primary open-angle glaucoma or pseudoexfoliation glaucoma. Twenty patients were treated with latanoprost 0.0015% twice daily or 0.005% once daily for 3 weeks in a cross-over design. Ten patients received timolol 0.5% twice daily as control. • Results: Latanoprost 0.005% once daily reduced IOP (± SEM) more effectively than latanoprost 0.0015% twice daily (9.8±0.9 mm Hg and 6.7±0.9 mm Hg, respectively). There was a statistically significant increase in the aqueous humour protein concentration within the timolol group (P=0.004), but not within the latanoprost group (P=0.97). There was no statistically significant difference in the change in aqueous humour protein concentration from baseline between latanoprost and timolol groups (P=0.08). No statistically significant difference in conjunctival hyperemia between the two latanoprost regimens was found (P=0.37). • Conclusion: Latanoprost 0.005% once daily reduced IOP more effectively than latanoprost 0.0015% twice daily (P<0.001). Latanoprost had no statistically or clinically significant effect on the blood-aqueous barrier. There was no difference in hyperemia between the two regimens. Both concentrations of latanoprost reduced IOP at least as well as timolol 0.5% eye drops.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Alm A, Villumsen J (1991) PhXA34, a new potent ocular hypotensive drug. A study on dose-response relationship and on aqueous humor dynamics in healthy volunteers. Arch Ophthalmol 109:1564–1568

    Google Scholar 

  2. Alm A, Villumsen J, Törnquist P, Mandahl A, Airaksinen J, Tuulonen A, Marsk A, Resul B, Stjernschantz J (1993) Intraocular pressure reducing effect of PhXA41 in patients with increased eye pressure: a one-month study. Ophthalmology 100:1312–1317

    Google Scholar 

  3. Alm A, Stjernschantz J, Scandinavian Latanoprost Study Group (1995) Effects on intraocular pressure and side effects of 0.005% Latanoprost applied once daily, evening or morning. A comparison with timolol. Ophthalmology 102:1743–1752

    Google Scholar 

  4. Alm A, Widengård I, Kjellgren D, Söderström M, Fristrum B, Heijl A, Stjernschantz J (1995) Latanoprost administered once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol. Br J Ophthalmol 79:12–16

    Google Scholar 

  5. Araie M, Mori M, Oshika T (1990) In vivo measurements of aqueous flare in human eyes. Diurnal variation and drug effects. In: Krieglstein GK (ed) Glaucoma update IV. Springer, Berlin Heidelberg New York, pp 52–56

    Google Scholar 

  6. Bito LZ, Camras CB, Gum GG, Resul B (1989) The ocular hypotensive effects of topically applied prostaglandins on eyes of experimental animals. Prog Clin Biol Res 312:349–368

    Google Scholar 

  7. Brubaker RF (1989) Fluorophotometric studies of prostaglandin effects on the human eye: the lack of association of reduced intraocular pressure with altered flow of barrier function. In: Bito LZ, Stjernschantz J (eds) The ocular effects of prostaglandins and other eicosanoids. Liss, New York, pp 477–481

    Google Scholar 

  8. Camras CB, United States Latanoprost Study Group (1996) Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma. A six-month, masked, multicenter trial in the United States. Ophthalmology 103: 138–147

    Google Scholar 

  9. Crawford K, Kaufman PL, Gabelt BT (1987) Effects of topical PGF2α on aqueous humour dynamics in cynomolgus monkeys. Curr Eye Res 6:1034–1044

    Google Scholar 

  10. Diestelhorst M, Schmidt B, Konen W, Mester U, Sunder Raj P (1996) Efficacy and tolerance of diclofenac sodium 0.1 %, flurbiprofen 0.03%, and indomethacin 1.0% in controlling postoperative inflammation. J Cataract Refract Surg 22:788–793

    Google Scholar 

  11. Friström B, Nilsson SEG (1993) Interaction of PhXA41 a new prostaglandin analogue with pilocarpine. A study in patients with elevated intraocular pressure. Arch Ophthalmol 111:662–665

    Google Scholar 

  12. Gabelt BT, Kaufman PL (1989) Prostaglandin F2α increases inveoscleral outflow in the cynomolgus monkey. Exp Eye Res 49:389–402

    Google Scholar 

  13. Gabelt BT, Kaufman PL (1990) The effect of prostaglandin F2α on trabecular outflow facility in cynomolgus monkeys. Exp Eye Res 51:87–91

    Google Scholar 

  14. Giuffré G (1985) The effects of prostaglandin F2α in the human eye. Graefes Arch Clin Exp Ophthalmol 222:139–141

    Google Scholar 

  15. Hotehama Y, Mishima HK (1993) Clinical efficacy of PhXA34 and PhXA41, two novel prostaglandin F2α-isopropyl ester analogues for glaucoma treatment. Jpn J Ophthal mol 37:259–269

    Google Scholar 

  16. Hotehama Y, Mishima HK, Kitazawa Y, Masuda K (1993) Ocular hypotensive effect of PhXA41 in patients with ocular hypertension or primary open-angle glaucoma. Jpn J Ophthalmol 37:270–274

    Google Scholar 

  17. Kjellgren D, Douglas G, Mikelberg FS, Drance SM, Alm A (1995) The short-time effect of latanoprost on the intraocular pressure in normal pressure glaucoma. Acta Ophthalmol 73:233–236

    Google Scholar 

  18. Lasky M, Ticho U, Nesher R, Melamed S, Glovinsky J (1994) Comparison of two dose regimens of latanoprost in patients with open-angle glaucoma or ocular hypertension. Abstract SP576, Proceedings of 27th International Congress of Ophthalmology, Toronto, Canada, June

  19. Nagasubramanian S, Sheth GP, Hitchings RA, Stjernschantz J (1993) Intraocular pressure-reducing effect of PhXA41 in ocular hypertension. Ophthalmology 100:1305–1311

    Google Scholar 

  20. Nilsson SFE, Samuelsson M, Bill A, Stjernschantz J (1989) Increased uveoscleral outflow as a possible mechanism of ocular hypotension caused by prostaglandin F2α 1-isopropylester in the cynomolgus monkey. Exp Eye Res 48:707–716

    Google Scholar 

  21. Selén G, Stjernschantz J, Resul B (1996) Prostaglandin-induced iridial pigmentation in primates. Surv Ophthalmol (in press)

  22. Stjernschantz J, Resul B (1992) Phenyl substituted prostaglandin analogs for glaucoma treatment. Drugs Future 17:691–704

    Google Scholar 

  23. Stjernschantz J, Nilsson SFE, Astin M (1989) Vasodynamic and angiogenic effects of eicosanoids in the eye. In: Bito LZ, Stjernschantz J (eds) The ocular effects of prostaglandins and other eicosanoids. Liss, New York, pp 155–170

    Google Scholar 

  24. Stur M, Grabner G, Huber-Spitzy V, Schreiner J, Haddad R (1986) Effect of timolol on aqueous humour protein concentration in the human eye. Arch Ophthalmol 104:899–900

    Google Scholar 

  25. Tamm E, Rittig M, Lütjen-Drecoll E (1990) Elektromikroskopische und immunohistochemische Untersuchungen zur augendrucksenkenden Wirkung von Prostaglandin F2α. Fortschr Ophthalmol 87:623–629

    Google Scholar 

  26. Toris CB, Camras CB, Yablonski ME (1993) Effects of PhXA41, a new prostaglandin F2α analog, on aqueous humour dynamics in human eyes. Ophthalmology 100:1297–1304

    Google Scholar 

  27. Villumsen J, Alm A (1989) Prostaglandin F2α-isopropylester eye drops: effects in normal human eyes. Br J Ophthalmol 73:419–425

    Google Scholar 

  28. Villumsen J, Alm A (1992) PhXA34 a prostaglandin F2α analogue. Effect on intraocular pressure in patients with ocular hypotension. Br J Ophthalmol 76:214–217

    Google Scholar 

  29. Villumsen J, Alm A, Söderström M (1989) Prostaglandin F2α-isopropy-tester eye drops: effect on intraocular pressure in open-angle glaucoma. Br J Ophthalmol 73:975–979

    Google Scholar 

  30. Watson P, Stjernschantz J, Latanoprost Study Group (1996) A sixmonth, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. Ophthalmology 103:126–137

    Google Scholar 

  31. Ziai N, Dolan JW, Kacere RD, Brubaker RF (1993) The effects on aqueous dynamics of PhXA41, a new prostaglandin F2α analogue, after topical application in normal and ocular hypertensive human eyes. Arch Ophthalmol 111:1351–1358

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Ophthalmology, University of Cologne, Joseph-Stelzmann-Strasse 9, D-50931, Cologne, Germany

    Michael Diestelhorst, Sigrid Roters & Günter K. Krieglstein

Authors
  1. Michael Diestelhorst
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sigrid Roters
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Günter K. Krieglstein
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Diestelhorst, M., Roters, S. & Krieglstein, G.K. The effect of latanoprost 0.005% once daily versus 0.0015% twice daily on intraocular pressure and aqueous humour protein concentration in glaucoma patients. A randomized, double-masked comparison with timolol 0.5%. Graefe's Arch Clin Exp Ophthalmol 235, 20–26 (1997). https://doi.org/10.1007/BF01007833

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01007833

Keywords

Search

Navigation